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Abstract: Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for 
significant morbidity and mortality from cardioembolic complications like stroke. As a result, 
atrial fibrillation patients are risk-stratified using the CHADS
2
 or CHA
2
DS
2
-VASc scoring 
systems. Those at intermediate-to-high risk have traditionally been treated with therapeutic 
anticoagulation with warfarin for stroke prevention. Although effective, warfarin use is fraught 
with multiple concerns, such as a narrow therapeutic window, drug–drug and drug–food interac-
tions, and excessive bleeding. Novel oral anticoagulant agents have recently become available 
as viable alternatives for warfarin therapy. Direct thrombin inhibitor dabigatran and factor Xa 
inhibitors like rivaroxaban and apixaban have already been approved by the US Food and Drug 
Administration (FDA) for stroke prevention in patients with nonvalvular atrial fibrillation. 
Edoxaban is the latest oral direct factor Xa inhibitor studied in the largest novel oral antico-
agulant trial so far: ENGAGE AF-TIMI 48. Treatment with a 30 mg or 60 mg daily dose of 
edoxaban was found to be noninferior to dose-adjusted warfarin in reducing the rate of stroke 
and systemic embolism in patients with nonvalvular atrial fibrillation, with a lower incidence 
of bleeding complications and cardiovascular deaths. Edoxaban was recently reviewed by an 
FDA advisory committee and recommended as a stroke-prophylaxis agent. Once approved, it 
promises to provide another useful alternative to warfarin therapy.
Keywords: atrial fibrillation, stroke prevention, novel oral anticoagulants, factor Xa inhibitors, 
edoxaban
Clinical impact summary for edoxaban in the stroke prevention in patients with 
nonvalvular atrial fibrillation
Outcome 
measure
Evidence Implications
Disease-oriented evidence
Composite of stroke  
and systemic 
embolism
1.18% per year in patients receiving 60 mg 
edoxaban (HR 0.79, 95% Ci 0.63–0.99; 
P,0.001) and 1.61% per year in patients 
receiving 30 mg edoxaban (HR 1.07, 
95% Ci 0.87–1.31; P=0.005) compared with 
1.50% per year in patients receiving dose-
adjusted warfarin
Compared with warfarin, 
treatment with edoxaban 
at both doses was 
noninferior in reducing 
the rate of stroke and 
systemic embolism in 
patients with NvAF
Stroke 1.49% per year in patients receiving 60 mg 
edoxaban (HR 0.88, 95% Ci 0.75–1.03; P=0.11) 
and 1.91% per year in patients receiving 30 mg 
edoxaban (HR 1.13, 95% Ci 0.97–1.31; P=0.12) 
compared with 1.69% per year in patients 
receiving dose-adjusted warfarin
Compared with warfarin, 
treatment with both 
doses of edoxaban was 
associated with similar 
risk of stroke
(Continued)
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(Continued)
Outcome 
measure
Evidence Implications
Hemorrhagic stroke 0.26% per year in patients receiving 60 mg 
edoxaban (HR 0.54, 95% Ci 0.38–0.77; P,0.001) 
and 0.16% per year in patients receiving 30 mg 
edoxaban (HR 0.33, 95% Ci 0.22–0.50; P,0.001) 
compared with 0.47% per year in patients 
receiving dose-adjusted warfarin
Compared with warfarin, 
treatment with either 
dose of edoxaban 
was associated with a 
significantly lower risk of 
hemorrhagic stroke
Death from  
any cause
3.99% per year in patients receiving 60 mg 
edoxaban (HR 0.92, 95% Ci 0.83–1.01; 
P=0.08) and 3.8% per year in patients 
receiving 30 mg edoxaban (HR 0.87, 95% Ci 
0.79–0.96; P=0.006) compared with 4.35% 
per year in patients receiving dose-adjusted 
warfarin
Compared with warfarin, 
treatment with 60 mg 
edoxaban was associated 
with marginally lower 
risk of death and 30 mg 
edoxaban was associated 
with significantly lower risk 
of death from any cause
Patient-oriented evidence
Bleeding complication
  iSTH major 
bleeding
2.75% per year in patients receiving 60 
mg edoxaban (HR 0.80, 95% Ci 0.71–0.91; 
P,0.001) and 1.61% per year in patients 
receiving 30 mg edoxaban (HR 0.47, 95% Ci 
0.41–0.55; P,0.001) compared with 3.43% 
per year in patients receiving dose-adjusted 
warfarin
Compared with warfarin, 
treatment with either 
dose of edoxaban was 
associated with a lower 
risk of iSTH major 
bleeding
  intracranial 
bleeding
0.39% per year in patients receiving 60 
mg edoxaban (HR 0.47, 95% Ci 0.34–0.63; 
P,0.001) and 0.26% per year in patients 
receiving 30 mg edoxaban (HR 0.30, 95% Ci 
0.21–0.43; P,0.001) compared with 0.85% 
per year in patients receiving dose-adjusted 
warfarin
Compared with warfarin, 
treatment with either 
dose of edoxaban 
was associated with a 
significantly lower risk of 
intracranial bleeding
  Gastrointestinal  
bleeding
1.51% per year in patients receiving 60 mg 
edoxaban (HR 1.23, 95% Ci 1.02–1.50; P=0.03) 
and 0.82% per year in patients receiving 30 mg 
edoxaban (HR 0.67, 95% Ci 0.53–0.83; P,0.001) 
compared with 1.23% per year in patients 
receiving dose-adjusted warfarin
Compared with warfarin, 
treatment with 60 mg 
edoxaban had higher 
and 30 mg edoxaban had 
significantly lower risk of 
gastrointestinal bleeding
  Major or clinically  
relevant nonmajor  
bleeding
11.1% per year in patients receiving 60 
mg edoxaban (HR 0.86, 95% Ci 0.80–0.92; 
P,0.001) and 7.97% per year in patients 
receiving 30 mg edoxaban (HR 0.62, 95% Ci 
0.57–0.67; P,0.001) compared with 13.02% 
per year in patients receiving dose-adjusted 
warfarin
Compared with warfarin, 
treatment with edoxaban 
at either dose was 
associated with a lower 
risk of major or clinically 
relevant nonmajor 
bleeding
Net clinical outcome
Composite of stroke, 
systemic embolic 
event, major bleeding, 
or death from any 
cause
7.26% per year in patients receiving 60 mg 
edoxaban (HR 0.89, 95% Ci 0.83–0.96; 
P=0.003) and 6.79% per year in patients 
receiving 30 mg edoxaban (HR 0.83, 95% Ci 
0.77–0.90; P,0.001) compared with 8.11% 
per year in patients receiving dose-adjusted 
warfarin
Compared with warfarin, 
treatment with either 
dose of edoxaban 
was associated with 
improved net clinical 
outcome
Composite of 
disabling stroke, life-
threatening bleeding, 
or death from any 
cause
4.64% per year in patients receiving 60 
mg edoxaban (HR 0.88, 95% Ci 0.81–0.97; 
P=0.008) and 4.38% per year in patients 
receiving 30 mg edoxaban (HR 0.83, 95% Ci 
0.76–0.91; P,0.001) compared with 5.23% 
per year in patients receiving dose-adjusted 
warfarin
Same as above
(Continued)
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Edoxaban for stroke prevention in atrial fibrillation
Introduction
Edoxaban belongs to the family of novel oral anticoagulants 
(NOACs), and is a direct factor Xa inhibitor. It has been 
studied in a large Phase III trial (ENGAGE AF-TIMI 48),1 
and was recently reviewed and recommended for approval 
by a US Food and Drug Administration (FDA) advisory 
committee for its use for stroke prevention in patients with 
atrial fibrillation (AF). AF is the most common arrhythmia 
encountered in clinical practice. Patients with AF are at 
a high risk of developing cardioembolic strokes, leading 
to considerable morbidity and mortality.2,3 The vitamin K 
antagonist (VKA) warfarin has traditionally been used for 
stroke prevention in these individuals, but effective use of 
this medication is encumbered by its delayed onset, narrow 
therapeutic window, numerous drug–drug and drug–food 
interactions, and need for regular monitoring. This has 
prompted the recent advent of newer agents including direct 
thrombin inhibitors like dabigatran, and factor Xa inhibitors 
like rivaroxaban and apixaban. Once available, edoxaban 
promises to be an important addition to the armamentarium 
of newer OACs for stroke prevention in patients with non-
valvular AF (NVAF).
Atrial fibrillation and risk of stroke
Patients with AF are susceptible to developing cardioembolic 
stroke, and are in fact five times as likely to suffer a stroke 
as patients without AF.4 In addition, AF-related strokes have 
poorer outcomes than non-AF-related strokes, including 
worse functional impairment, recurrence, and death.5
For early identification and better characterization of 
patients at high risk of developing strokes from AF, mul-
tiple risk scores have been developed. The CHADS
2
 risk-
scoring system is a well-validated method that utilizes five 
variables to determine the risk of cardioembolic stroke.6 
Congestive heart failure, hypertension, diabetes mellitus, and 
age $75 years are each assigned 1 point. History of previous 
stroke or transient ischemic attack is assigned 2 points. The 
newer CHA
2
DS
2
-VASc score added three new risk factors 
(history of vascular disease, age 65–74 years, and female 
sex) to the risk assessment.7 In the CHA
2
DS
2
-VASc scheme, 
age $75 years is assigned 2 points, at par with previous stroke 
and transient ischemic attack. Therefore, women and elderly 
patients ($75 years) who were previously identified as at 
intermediate risk are now placed in the high-risk category, 
warranting full anticoagulation.
The 2014 American Heart Association (AHA)/American 
College of Cardiology (ACC) AF guidelines recommend the 
use of CHA
2
DS
2
-VASc scoring system in place of CHADS
2
 
for stroke-risk assessment.8 For high-risk patients with NVAF 
(CHA
2
DS
2
-VASc score $2), oral anticoagulation therapy is 
given the strongest (class I) recommendation. For patients with 
an intermediate-risk score of 1, options of anticoagulation, 
aspirin, or no therapy are left to the discretion of the provider 
(class IIb). In low-risk patients with a risk score of 0, no anti-
thrombotic therapy is considered reasonable (class IIa).
Vitamin K antagonist  
for stroke prevention
The VKA warfarin has traditionally been used for patients 
with AF, and has been shown to reduce the risk of stroke 
and mortality.9 However, effective use of this medication 
is fraught with multiple impediments, contributing to sig-
nificant underutilization.10 Warfarin has a slow onset of 
action, narrow therapeutic window, variable cytochrome 
P450-dependent metabolism, and significant drug–drug and 
drug–food interactions.10–13 As a result, anticoagulation with 
warfarin is unreliable, necessitating the need for frequent and 
regular international normalized ratio (INR) monitoring and 
dosage adjustment. The therapeutic window for warfarin is 
narrow. Subtherapeutic anticoagulation exposes patients to 
(Continued)
Outcome 
measure
Evidence Implications
Composite of stroke, 
systemic embolic 
event, life-
threatening bleeding, 
or death
5.3% per year in patients receiving 60 mg 
edoxaban (HR 0.88,  
95% Ci 0.81–0.96; P=0.003) and 5.37% per 
year in patients receiving  
30 mg edoxaban (HR 0.89, 95% Ci 0.82–0.97; 
P=0.007) compared with 6.02% per year in 
patients receiving dose-adjusted warfarin
Same as above
Quality-of-life  
measures
Not available
Economic evidence Not available
Abbreviations: HR, hazard ratio; CI, confidence interval; NVAF, nonvalvular atrial fibrillation; ISTH, International 
Society on Thrombosis and Haemostasis.
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 cardioembolic events, and supratherapeutic anticoagulation 
subjects them to bleeding complications.14 Unfortunately, 
in most patients, therapeutic anticoagulation is maintained 
less than a third of the time. Even in recent randomized 
control trials, where concerted efforts were made to keep 
most patients at the target INR, the time in therapeutic range 
was able to be maintained only in 62%–64% of patients. In 
the ROCKET-AF trial, time in therapeutic range was merely 
55%. In addition, frequent doctor and laboratory visits make 
warfarin therapy expensive and inconvenient.15
Elderly patients with cognitive impairment, physical limi-
tations, and frequent falls are especially vulnerable to bleeding 
risk with warfarin. Another high-risk group is patients with 
severe renal impairment. Not only are these patients at an 
increased risk of strokes but they are also prone to increased 
bleeding with warfarin therapy, due to underlying platelet-
dysfunction and coagulation-pathway abnormalities.16–18
Since the 1950s, warfarin has been the main OAC 
available for AF patients. There has been a need for newer 
OACs that would have a rapid onset of action, insignificant 
 drug–drug and drug–food interactions, and provide reliable 
stroke prevention by having a predictable effect, without the 
need for frequent monitoring.
Antiplatelet agents
Though dose-adjusted warfarin is signif icantly more 
effective than antiplatelet therapy (meta-analysis of 12 
trials [n=12,963] showed relative risk reduction of 39% 
 [confidence interval {CI} 22%–52%]),19 antiplatelet agents 
have long been used as an alternative in patients deemed to 
be at low risk of stroke or with contraindications to warfarin. 
Aspirin use was given a class I recommendation for use in 
patients with a CHADS
2
 score of 0 and class IIa recom-
mendation patients with a CHADS
2
 score of 1 as per 2006 
ACC/AHA AF guidelines.20 However, over time, evidence 
has accumulated against aspirin use for this indication. A 
meta-analysis by Hart et al19 looked at seven trials (n=3,990) 
comparing aspirin at different doses to placebo/no treatment 
for primary and secondary stroke prevention in patients with 
AF, and found no significant difference other than in one 
trial (SPAF-121). Risk reduction of 19% (CI −1% to 35%) 
was seen with aspirin, but the CI encompassing 0 questioned 
any real benefit at all.
Additionally, the AVERROES trial22 showed that in 
patients unsuitable for warfarin therapy, the factor Xa 
inhibitor apixaban reduced almost 50% more strokes than 
aspirin (relative risk [RR] 0.46 [95% CI 0.33–0.64]) during 
a 1-year follow-up.
The 2014 AF guidelines have thus moved away from 
aspirin for stroke prevention. No antithrombotic use is now 
considered reasonable for patients with a CHA
2
DS
2
-VASc 
score of 0 (class IIa), and the use of aspirin may be considered 
for CHA
2
DS
2
-VASc score of 1 (class IIB).8
Dual-antiplatelet therapy with aspirin and clopidogrel 
as an alternative to warfarin in patients with a CHADS
2
 
score $1 was evaluated in the ACTIVE W trial.23 The trial 
was stopped early, due to marked superiority of warfarin over 
dual antiplatelets (RR 1.44 [95% CI 1.18–1.76]; P=0.0003) 
for stroke prevention. The ACTIVE A (a separate arm 
of ACTIVE W) trial found that dual-antiplatelet therapy 
prevented more strokes than aspirin alone, but also caused 
significantly more bleeding.24 Based on these trials, the 
2011 ACC/AHA focused update of the 2006 AF guidelines 
gave combination therapy with aspirin and clopidogrel a 
class IIb recommendation for stroke prevention in patients 
unwilling or unsuitable for anticoagulant therapy.25 However, 
 dual-antiplatelet therapy has not been given any recommenda-
tion in the 2014 guidelines.
Novel oral anticoagulant agents
Direct thrombin inhibitors
Dabigatran is a direct thrombin inhibitor. It was the first 
NOAC approved by the FDA for stroke prevention in patients 
with NVAF. The RE-LY study26 was a multicenter, random-
ized trial that tested the efficacy and safety of 110 mg twice 
a day and 150 mg twice a day dosing of dabigatran etexilate 
with open-label dose-adjusted warfarin in 18,113 patients. 
After a mean follow-up of 2 years, dabigatran 150 mg twice a 
day was found to be superior in efficacy (stroke and systemic 
embolic event [SEE] prevention) with similar major bleeding 
as warfarin, and 110 mg twice a day was found to be non-
inferior in efficacy with less major bleeding than warfarin. 
Both doses showed less intracranial bleeding than warfarin. 
 However, rates of myocardial infarction and adverse effects 
like dyspepsia were somewhat higher in the dabigatran 
groups. Based on these results, the FDA in October 2010 
approved the 150 mg twice-a-day regimen (as well as 75 mg 
twice a day for patients with severe renal impairment) for 
stroke prevention in AF patients. A Canadian regulatory 
authority, the European Medicines Agency, and many other 
authorities worldwide approved both 150 mg and 110 mg 
twice-daily dosing of the drug.
Soon after dabigatran’s approval, there were postmar-
keting reports of increased gastrointestinal, intracranial, 
and fatal bleeds. In response, the FDA did a mini-sentinel 
analysis of insurance claims and administrative data, but 
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found no increased bleeding with dabigatran compared to 
warfarin.27 The RELY-ABLE study followed 48% of patients 
originally assigned to dabigatran in the RE-LY study for 
an additional 2.3 years, and found a higher rate of major 
bleeding with dabigatran 150 mg twice daily in comparison 
with 110 mg, with similar rates of stroke and death.28 Use of 
dabigatran has received a class I indication in the 2014 ACC/
AHA AF guidelines for stroke prevention in patients with a 
 CHA
2
DS
2
-VASs score of $2 and in patients unable to main-
tain a therapeutic INR. Lower-dose direct thrombin inhibi-
tors may be considered for patients with  moderate-to-severe 
chronic kidney disease (class IIb). They should not be used 
in patients with end-stage renal disease or with mechanical 
valves (class III).8
Factor Xa inhibitors
The coagulation cascade involves stepwise amplification 
with one molecule of factor Xa generating a thousand mol-
ecules of thrombin.29 Two factor Xa inhibitors – rivaroxaban 
and apixaban – have been approved by the FDA for stroke 
prevention in AF.
Rivaroxaban was evaluated for stroke prevention in 
 moderate- to high-risk AF patients in the ROCKET-AF trial.30 
This large multicenter trial (n=14,264, median follow-up 
1.9 years) showed rivaroxaban at a 15–20 mg daily dose to be 
noninferior to dose-adjusted warfarin in preventing stroke and 
SEEs. There was no difference in major and minor bleeding 
rates between the groups, though intracranial bleeding was 
less and gastrointestinal bleeding was more with rivaroxaban. 
Despite concerns about once-a-day administration of a drug 
with a relatively short half-life, rivaroxaban was approved by 
the FDA for stroke prevention for AF patients in November 
2011. Another concern with rivaroxaban was a much higher 
rate of stroke or systemic embolism seen compared to war-
farin (31 versus 12 detected events) between days 2 and 7 
after discontinuation of randomized treatment.31
Apixaban was the second factor Xa inhibitor that was 
evaluated in two major randomized control trials. The 
AVERROES trial randomized 5,600 patients unsuitable for 
VKA therapy due to difficult-to-control INR or bleeding to 
apixaban 5 mg twice a day or aspirin 81–324 mg daily.22 
The study was terminated early after a median follow-up of 
1 year. Apixaban reduced significantly more strokes than 
aspirin (RR 0.46, 95% CI 0.33–0.64). Subsequently, apixaban 
5 mg twice a day was compared to dose-adjusted warfarin 
in the ARISTOTLE trial.32 This double-blinded randomized 
control trial (n=18,201, median follow-up 1.8 years) showed 
that apixaban was superior to warfarin in stroke and SEE 
prevention, with significantly lower overall and intracranial 
bleeding and significantly lower all-cause mortality. Based 
on these trials, apixaban was approved by the FDA for stroke 
prevention in December 2012.
The use of factor Xa and thrombin inhibitors was 
endorsed by the 2012 ESC update of AF guidelines, where 
they received a class I indication for use for stroke prevention 
in AF patients and IIa recommendation for preferential 
use over dose-adjusted warfarin.33 Similarly, the  Canadian 
 Cardiovascular Society and American Academy of  Neurology 
gave favorable recommendations for their use in their 2012 
AF guidelines update.34,52 Dabigatran, rivaroxaban, and 
apixaban received a class I indication in the 2014 ACC/
AHA AF guidelines for stroke prevention in patients with 
a CHA
2
DS
2
-VASs score of $2 and in patients unable to 
maintain a therapeutic INR.8
The newest addition to the family of NOACs and the class 
of factor Xa inhibitors, edoxaban is currently undergoing 
FDA review. The following is a brief review of edoxaban for 
stroke prevention in NVAF.
Edoxaban – brief pharmacology
Edoxaban is a rapidly acting, oral, selective factor Xa 
 inhibitor. It is readily absorbed from the intestines, and has 
a 62% oral bioavailabilty.35 Diet has no clinically significant 
effect on edoxaban activity36 and it reaches plasma peak 
concentration and anti-factor Xa activity in 1–2 hours.37,38 
Edoxaban has a half-life of 10–14 hours, but its anti-factor Xa 
activity remains above baseline for 24 hours. Seventy percent 
of the drug is excreted unchanged in urine and feces.39
Edoxaban is a substrate of P-glycoprotein (P-gp),40 and 
coadministration of potent P-gp inhibitors like quinidine, 
verapamil, and dronedarone increases edoxaban exposure.41 
Accordingly, in the ENGAGE AF-TIMI 48 trial, patients taking 
these medications were administered half doses of  edoxaban. 
Low-dose aspirin and nonsteroidal  anti- inflammatory 
drugs like naproxen are well tolerated in patients receiving 
edoxaban.42 Edoxaban can also be safely administered after 
12 hours of enoxaparin use.43
Edoxaban: clinical trials  
in stroke prevention
Phase i clinical trials
In a safety, tolerability, pharmacokinetic, and pharmacody-
namic study, 85 healthy volunteers received a single dose 
(10, 30, 60, 90, 120, or 150 mg once only) and 36 volunteers 
received multiple doses of edoxaban (90 mg daily, 120 mg 
daily, or 60 mg twice a day).38 Plasma concentrations of 
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edoxaban were proportional to the dose, with low intersubject 
variability. Elevation of activated partial thromboplastin time, 
prothrombin time and INR, and reduction in activated factor 
X activity were seen within the first few hours of administra-
tion and returned to baseline in 24 to 36 hours. Edoxaban 
was well tolerated in both groups, and no dose-dependent 
increase in serious adverse events was documented.
Phase ii clinical trials
In a multicenter, multinational Phase II clinical trial of edoxaban, 
four doses (30 mg daily, 60 mg daily, 30 mg twice a day, and 60 
mg twice a day) were compared with dose-adjusted warfarin (tar-
get INR 2–3) in 1,146 patients with NVAF.44 Patients randomized 
to one of the five groups were followed for 12 weeks to look for 
incidence of major and nonmajor bleeding. Bleeding rates were 
similar in patients on once-a-day dosage of edoxaban (3.0% in 
30 mg daily and 3.8% in 60 mg daily) to those on dose-adjusted 
warfarin (3.2%), but significantly higher in those on twice-a-
day dosing (7.8% in 30 mg twice daily and 10.6% 60 mg twice 
daily). Based on these results, a once-daily dosing of edoxaban 
was selected for Phase III clinical trials. Daily dosages of 30, 
45, and 60 mg of edoxaban were compared to dose-adjusted 
warfarin in another trial in 536 Japanese patients with NVAF.45 
No statistically significant difference was found in symptomatic 
and asymptomatic bleeding at 12 weeks of follow-up. On the 
basis of exposure–response modeling and pharmacokinetics 
from 1,281 subjects, 30 mg and 60 mg once-daily doses of 
edoxaban were chosen to undergo Phase III trials, with 50% 
dose reductions for moderate renal impairment or concomitant 
P-gp inhibitor use.46
Phase iii clinical trial
The efficacy and safety of edoxaban compared to warfarin was 
evaluated in the ENGAGE AF-TIMI 48 trial.1 This was a large 
multicenter, randomized, double-blind,  double-dummy trail that 
enrolled 21,105 patients at 1,393 hospitals from 46 countries. 
A noninferiority study design was used to compare two oral 
doses of edoxaban (30 mg and 60 mg daily) to warfarin in 
patients with AF and moderate-to-high risk of stroke.
Patients were enrolled during a 2-year period from 
November 2008 through November 2010. The study popula-
tion included patients $21 years of age, with AF documented 
within 1 year preceding randomization and a CHADS
2
 score 
of 2 or more. Principal exclusion criteria included transient 
AF secondary to a reversible cause, creatinine clearance 
of ,30 mL/min, use of dual-antiplatelet therapy, high bleed-
ing risk, moderate-to-severe mitral stenosis, mechanical heart 
valves, other indications for anticoagulation, stroke, acute 
coronary syndrome, or percutaneous coronary intervention 
within the previous 30 days, pregnancy, malignancy, and life 
expectancy ,12 months, among others.47
Patients were randomized in a 1:1:1 fashion to a daily 
oral dose of 30 mg (low exposure) or 60 mg (high exposure) 
edoxaban or warfarin titrated to an INR of 2–3.2 In patients 
with moderate renal dysfunction (creatinine clearance 
30–50 mL/min), body weight less than 60 kg or concomi-
tant use of potent P-gp inhibitors (verapamil, quinidine, or 
dronedarone), a dose reduction of 50% to the edoxaban 
arms was instituted to prevent excess bleeding. According to 
the double-dummy design, patients on edoxaban received 
placebo-matching warfarin and patients on warfarin received 
placebo-matching edoxaban. Additionally, patients in the 
edoxaban arms had sham blood draws for INR checks. 
 Regular INR checks and clinic visits were carried out.
Efficacy and safety outcomes were evaluated. The primary 
efficacy end point was a composite of stroke (ischemic or hem-
orrhagic) and SEEs. The primary safety end point was major 
bleeding as per the International Society on  Thrombosis and 
Hemostasis, defined as meeting one or more of the following 
criteria: fatal bleeding, symptomatic bleeding in a critical area 
or organ, or clinically overt bleeding causing a $2.0 g/dL drop 
in hemoglobin. Stroke, systemic embolism, cardiac death, and 
all-cause death were assessed separately and in combination 
for secondary end points. Bleeding at different locations, of 
varying intensity, and defined by other definitions was also 
assessed. An independent clinical end-point committee that 
was blinded to study assignment adjudicated all events.
The median age of the study population was 72 years, 
and their mean CHADS
2
 score was 2.8. Patients randomized 
to warfarin were in the therapeutic range 68.4% of the time. 
Both groups were comparable in terms of their baseline char-
acteristics (Table 1). After a median follow-up of 2.8 years, 
the annual rate of primary outcome (stroke and/or SEE) for 
patients in the high-dose edoxaban group was 1.18% (hazard 
ratio [HR] 0.79, 97.5% CI 0.63–0.99; P,0.001 for noninferi-
ority, P=0.02 for superiority), and for patients in the low-dose 
edoxaban group was 1.61% (HR 1.07, 97.5% CI 0.87–1.31; 
P=0.005 for noninferiority, P=0.44 for superiority) compared 
to 1.5% in the warfarin group (Table 2). Hemorrhagic stroke 
rates were significantly lower than warfarin (0.47%) in both 
the high-dose (0.26%) and low-dose edoxaban (0.16%) 
groups. A subsequent subanalysis of all cerebrovascular 
events showed that the rates of ischemic stroke or transient 
ischemic attack were similar with high-dose edoxaban 
(1.76% per year) and warfarin (1.73% per year) (P=0.81), 
but more frequent with low-dose edoxaban (2.48% per year, 
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Table 1 Baseline characteristics of patients in ENGAGE AF-TiMi 
48 trial
Variable Warfarin  
(n=7,036)
High-dose 
edoxaban 
(n=7,035)
Low-dose 
edoxaban 
(n=7,034)
Median age, years 72 72 72
Female sex, n (%) 2,641 (37.5) 2,669 (37.9) 2,730 (38.8)
Qualifying risk factors, n (%)
 Age $75 years 2,820 (40.1) 2,848 (40.5) 2,806 (39.9)
 Prior stroke or TiA 1,991 (28.3) 1,976 (28.1) 2,006 (28.5)
 Congestive heart failure 4,048 (57.5) 4,097 (58.2) 3,979 (56.6)
 Diabetes mellitus 2,521 (35.8) 2,559 (36.4) 2,544 (36.2)
 Hypertension 6,588 (93.6) 6,591 (93.7) 6,575 (93.5)
CHADS2 score
 Mean score ± SD 2.8±1.0 2.8±1.0 2.8±1.0
 2–3, n (%) 5,445 (77.4) 5,422 (77.1) 5,470 (77.8)
 4–6, n (%) 1,591 (22.6) 1,613 (22.9) 1,564 (22.2)
Note: From N Engl J Med, Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban 
versus warfarin in patients with atrial fibrillation. 369:2093–2104. Copyright © 2013. 
Adapted with permission from Massachusetts Medical Society.1
Abbreviations: TiA, transient ischemic attack; SD, standard deviation.
Table 2 Results of the ENGAGE AF-TiMi 48 trial
Warfarin  
event rate
High-dose  
edoxaban  
event rate
Low-dose  
edoxaban  
event rate
High-dose edoxaban  
versus warfarin
Low-dose edoxaban 
versus warfarin
Hazard ratio  
(95% CI)
P-value Hazard ratio  
(95% CI)
P-value
Efficacy outcomes
Stroke or systemic embolic  
event (primary) (noninferiority)
1.50 1.18 1.61 0.79 (0.63–0.99) ,0.001 1.07 (0.87–1.31) 0.005
 Stroke 1.69 1.49 1.91 0.88 (0.75–1.03) 0.11 1.13 (0.97–1.31) 0.12
 Hemorrhagic stroke 0.47 0.26 0.16 0.54 (0.38–0.77) ,0.001 0.33 (0.22–0.50) ,0.001
Stroke, systemic embolism or  
death from cardiovascular cause
4.43 3.85 4.23 0.87 (0.78–0.96) 0.005 0.95 (0.86–1.05) 0.32
Death from any cause 4.35 3.99 3.80 0.92 (0.83–1.01) 0.08 0.87 (0.79–0.96) 0.006
Death from cardiovascular cause 3.17 2.74 2.71 0.86 (0.77–0.97) 0.013 0.85 (0.76–0.96) 0.008
Safety outcomes
iSTH major bleeding (primary) 3.43 2.75 1.61 0.80 (0.71–0.91) ,0.001 0.47 (0.41–0.55) ,0.001
Fatal 0.38 0.21 0.13 0.55 (0.36–0.84) 0.006 0.35 (0.21–0.57) ,0.001
intracranial 0.85 0.39 0.26 0.47 (0.34–0.63) ,0.001 0.30 (0.21–0.43) ,0.001
Gastrointestinal 1.23 1.51 0.82 1.23 (1.02–1.50) 0.03 0.67 (0.53–0.83) ,0.001
Note: From N Engl J Med, Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. 369:2093–2104. Copyright © 2013. Adapted 
with permission from Massachusetts Medical Society.1
Abbreviations: CI, confidence interval; ISTH, International Society on Thrombosis and Haemostasis.
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P,0.001).48 Cardiovascular deaths were significantly low-
ered with high-dose (HR 0.86, 95% CI 0.77–0.97; P=0.01) 
and low-dose edoxaban use (HR 0.85, 95% CI 0.76–0.96; 
P=0.008) when compared to warfarin. A similar trend was 
seen in all-cause death reduction, which reached statistical 
significance only in the low-dose edoxaban group (HR 0.87, 
95% CI 0.79–0.96; P=0.006). There was no significant dif-
ference in myocardial infarction between groups.
With regard to the safety-outcome measures, major 
bleeding was significantly less with both doses of edoxaban. 
Compared to an event rate of 3.43% in the warfarin group, 
the high-dose edoxaban group had a major bleeding rate of 
2.75% (HR 0.80, 95% CI 0.71–0.91; P,0.001) and the low-
dose group had a rate of 1.61% (HR 0.47, 95% CI 0.41–0.55; 
P,0.001) (Table 2). Fatal and intracranial bleeds were less 
than warfarin in the high-dose edoxaban (HR 0.55 and 0.47, 
respectively) and low-dose edoxaban groups (HR 0.35 and 
0.30, respectively). Risk of gastrointestinal bleeding was 
increased in the high-dose edoxaban (HR 1.23) but reduced 
in the low-dose edoxaban group (HR 0.67) when compared 
to warfarin. Tolerability and adverse events with both doses 
of edoxaban and warfarin were comparable.
Comparison of edoxaban  
and other newer novel oral  
anticoagulant agents
Pharmacological characteristics of the four NOACs are 
described in Table 3.49 All four NOACs have been evaluated 
in large Phase III randomized control trials. Edoxaban 60 mg 
daily, apixaban 5 mg twice a day, and dabigatran 150 mg twice 
a day were shown to be superior to dose-adjusted warfarin in 
stroke and SEE prevention. Edoxaban 30 mg daily, rivaroxaban 
20 mg daily, and dabigatran 110 mg twice a day were found to be 
noninferior. The benefits of newer anticoagulants over warfarin 
were driven by a significant reduction in hemorrhagic strokes 
(reduced to half).50 Major bleeding rates were comparable to 
warfarin for dabigatran 150 mg twice a day and rivaroxaban 
20 mg daily. Edoxaban 30 mg and 60 mg daily, apixaban 5 mg 
twice a day, and dabigatran 110 mg twice a day had lower 
major bleeding rates than  warfarin. Intracranial bleeding was 
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Table 4 Comparative analysis of the novel anticoagulant agents 
in meta-analysis when compared against dose-adjusted warfarin
Stroke or systemic 
embolic events,  
RR (95% CI), P
Major bleeding,  
RR (95% CI), P
RELY (dabigatran  
150 mg twice daily)
0.66 (0.53–0.82),  
0.0001
0.94 (0.82–1.07), 
0.34
ROCKET (rivaroxaban  
20 mg daily)
0.88 (0.75–1.03),  
0.12
1.03 (0.90–1.18), 
0.72
ARISTOTLE (apixaban  
5 mg twice daily)
0.80 (0.67–0.95),  
0.012
0.71 (0.61–0.81), 
,0.0001
ENGAGE AF  
(edoxaban 60 mg daily)
0.88 (0.75–1.02),  
0.10
0.80 (0.71–0.90), 
0.0002
Combined 0.81 (0.73–0.91), 
,0.0001
0.86 (0.73–1.00), 
0.06
Note: Data from Ruff et al.50
Abbreviations: RR, relative risk; CI, confidence interval.
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lower with NOACs across the board. Edoxaban and apixaban 
were the only two to show mortality benefit when compared to 
warfarin. NOACs as a group were compared to dose-adjusted 
warfarin in a recent meta-analysis (Table 4).50 There has not 
been a head-to-head comparison of the NOACs.
Dabigatran 150 mg twice a day was approved by the FDA 
in 2010. Subsequent reports of increased bleeding with its 
use were somewhat dispelled by a mini-sentinel analysis by 
the FDA; however, higher major bleeding rates documented 
on long-term follow-up are concerning.28 Rivaroxaban 
20 mg once a day was approved in 2011 for stroke preven-
tion. The once-daily dosing of rivaroxaban was criticized by 
the FDA for not being supported by pharmacokinetic and 
 pharmacodynamic data. Apixaban 5 mg twice a day was 
Table 3 Comparison of pharmacological properties and overview of study design of Phase iii randomized clinical trials of new oral 
anticoagulants
Dabigatran Rivaroxaban Apixaban Edoxaban
Mechanism of action Direct thrombin  
inhibitor
Direct factor  
Xa inhibitor
Direct factor Xa inhibitor Direct factor Xa inhibitor
Oral bioavailability, % 6.5 80–100 50 62
Onset of action, hours 1–2 0.5–3 3–4 1–2
Half-life, hours 12–17 5–13 8–15 10–14
Renal elimination, % 85 66 (36 unchanged  
and 30 inactive  
metabolites)
27 50
Time to maximum  
inhibition, hours
0.5–2 1–4 1–4 1–2
Protein binding 35 92–95 87 55
interaction with food Minimal Minimal Minimal Minimal
interaction with  
amiodarone
Yes, use with  
caution
Yes, avoidance  
recommended
Yes, avoidance recommended Yes, use with caution
interaction with  
dronedarone
Yes, avoidance  
recommended
Yes, avoidance  
recommended
Yes, avoidance recommended Yes, dose reduction recommended
interaction with  
verapamil
Yes, dose reduction  
recommended
Yes, use with  
caution
Yes, use with caution Yes, dose reduction recommended
Regular lab  
monitoring required
No No No No
Reversal agent No No No PER977 (potential)
Phase iii clinical trial RELY ROCKET ARISTOTLE ENGAGE AF
Sample size 18,113 14,264 18,201 21,107
New treatment  
and dose
110 mg BiD and  
150 mg BiD
20 mg daily 5 mg BiD 30 mg daily and 60 mg daily
Dose adjustment No At randomization,  
15 mg for CrCl  
30–49 mL/min
At randomization, half dose for two 
or more of following: age $80 years, 
weight #60 kg, Cr $1.5 mg/dL
During trial, half dose for CrCl  
30–50 mL/min, weight ,60 kg or use 
of potent P-glycoprotein inhibitors
Design Noninferiority,  
open-label with blinded  
event adjudication
Noninferiority,  
double-blind
Noninferiority, double-blind Noninferiority, double-blind
Patients CHADS2 score $1 CHADS2  
score $2
CHADS2 score $1 CHADS2 score $2
Primary outcome Stroke or systemic  
embolism
Stroke or systemic  
embolism
Stroke or systemic embolism Stroke or systemic embolism
Safety outcome Major bleeding Major bleeding Major bleeding Major bleeding
FDA approval Yes Yes Yes Pending
Abbreviations: BiD, bis in die (twice a day); CrCl, creatinine clearance; FDA, US Food and Drug Administration.
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shown to be superior to warfarin in stroke prevention com-
pared to warfarin with less bleeding, and has been approved 
for this indication by the FDA since 2012, but its twice-a-
day dosing raises concerns about medication compliance. 
Once-daily dosing of edoxaban is backed by a large Phase II 
trial (unlike rivaroxaban), and has a definite advantage when 
compared to medications administered twice a day (dabigatran 
and  apixaban). This is especially important, as NVAF patients 
need lifelong therapy, and ease of administration is paramount 
for medication compliance. Since both doses of edoxaban 
have been proven to be efficacious in stroke prevention, the 
clinician had the potential choice of using low-dose edoxaban 
in patients with high bleeding risk and high doses in patients 
with low bleeding risk and high thromboembolic risk.
Excessive strokes were seen in the immediate period of 
transition from rivaroxaban and apixaban to warfarin in the 
ROCKET-AF and ARISTOTLE trials. This was due to an 
inability to achieve an adequate overlap from the discon-
tinuation of an NOAC (with a short half-life) and the delay 
in achieving therapeutic INR with warfarin. The ENGAGE 
 AF-TIMI 48 investigators designed a 14-day overlap proto-
col, and the choice of OAC at the end of the trial (VKA or an 
NOAC) was made by the physician and patient. In patients 
changing over to VKA, a 14-day transition kit of half-dose 
edoxaban was utilized and early and frequent INR testing 
was implemented. A warfarin-titration algorithm was used to 
ensure the adequacy of VKA therapy. No difference in stroke 
and bleeding rates were observed in groups that transitioned 
from edoxaban to warfarin and vice versa.51
NOACs have been evaluated in special situations like 
elective cardioversion for patients with NVAF.  Dabigatran, 
rivaroxaban, and apixaban have been shown to be as effica-
cious as warfarin in stroke prevention in patients undergoing 
cardioversion, with low stroke rates seen in all groups.53–55 
A current multicenter randomized interventional trial 
(ENSURE-AF, NCT02072434) is enrolling patients to evalu-
ate edoxaban for this indication.
An important caveat to the use of NOACs compared to 
warfarin has been the unavailability of effective reversal 
agents. PER977 has been tested in preclinical studies in 
reversing the anticoagulant effects of edoxaban, and has 
shown promise.56 The clinical availability of such an antidote 
may prove to be a definite advantage in favor of edoxaban.
Clinical implications and future 
direction
Edoxaban could be an excellent alternative for stroke preven-
tion in NVAF patients who are either intolerant to warfarin or 
have difficulty in maintaining therapeutic levels due to dietary 
or medication interactions. It would be ideal in patients with 
compliance issues, due to the convenient daily dosing. With 
dose reduction, edoxaban can be used in patients on antiar-
rhythmics like amiodarone, dronedarone, and verapamil. It 
has also been shown to be safe and efficacious in patients 
with moderate renal dysfunction.
Edoxaban was recently presented before the FDA advi-
sory panel. One of the major issues that were debated in this 
meeting was the subgroup analysis in patients with creatinine 
clearance $80 mL/min. In these patients with normal renal 
function, edoxaban use was associated with higher incidence 
of stroke and SEE. Both doses fared worse than dose-adjusted 
warfarin (HR for primary end point in edoxaban 60 mg ver-
sus warfarin was 1.41 [95% CI 0.97–2.05]). This resulted in 
one vote against the approval of edoxaban. However, citing 
the inherent pitfalls in interpreting subgroup analysis, espe-
cially when it went against the overall results of the trial, 
the  Cardiovascular and Renal Drugs Advisory Committee 
voted nine to one in favor of approving edoxaban for the 
prevention of stroke and SEE in patients with NVAF.57 Like 
other NOACs, edoxaban is being tested in clinical situations 
other than NVAF warranting anticoagulation. With further 
investigation, wider future application can be anticipated.
Summary
AF is the most common arrhythmia, and is a risk factor for 
cardioembolic strokes. Warfarin has traditionally been used for 
stroke prevention, but its use is limited by a narrow therapeutic 
window, significant drug–drug and drug–food interactions, 
need for frequent monitoring, and bleeding complications. 
The last decade has seen the advent of NOACs. Dabigatran, 
rivaroxaban, and apixaban have been approved by the FDA 
for stroke prevention in patients with AF. Edoxaban is the 
newest factor Xa inhibitor that has been evaluated in the larg-
est randomized controlled trial of all NOAC trials. High-dose 
edoxaban is superior and low-dose edoxaban noninferior to 
warfarin in preventing strokes and SEEs. Hemorrhagic strokes 
were lower with both doses, as were all major and intracranial 
bleeding. Gastrointestinal bleeding was lower than warfarin in 
the low-dose edoxaban group. Cardiovascular death was lower 
with edoxaban at both doses. Edoxaban has recently been 
recommended for approval by the FDA advisory  committee. 
Once available, it promises to be a safe and effective tool for 
stroke prevention in patients with AF.
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